Home>Topics>Companies>Sanofi S.A.

Sanofi S.A.

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Alirocumab successful in nine Phase 3 trials

    Headlines

    Wed, 30 Jul 2014

    Regeneron Pharmaceuticals (NASDAQ: REGN ) and partner Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) report that their PCSK9 inhibitor alirocumab met its primary endpoint of a greater percent reduction from baseline

  2. New Morningstar Analyst Report for Regeneron Pharmaceuticals Inc

    Stock Reports

    Wed, 30 Jul 2014

    Lucentis and Avastin. Sanofi has a significant ownership ..... Regeneron's partner Sanofi also owns about 17% of ..... the large holdings by Sanofi may dissuade other potential ..... monoclonal antibodies with Sanofi - Aventis in cholesterol reduction

  3. Sanofi , Regeneron drug cuts cholesterol in nine late-stage trials

    Headlines

    Wed, 30 Jul 2014

    PARIS, July 30 (Reuters) - A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage...

  4. Hungary launches probe against Sanofi - Aventis

    Headlines

    Tue, 29 Jul 2014

    BUDAPEST, July 29 (Reuters) - Hungary's competition watchdog GVH has raided the Hungarian headquarters of French drug maker Sanofi - Aventis as the first step of a proceedings against the firm for a suspected abuse of its dominant market position, GVH said on Tuesday.

  5. Sanofi cuts the cord on collaboration deal with KaloBios

    Headlines

    Mon, 28 Jul 2014

    Sanofi Pasteur ( SNY +0.5% ) ( OTCQB:SNYNF ) terminates ..... Pharmaceuticals ( KBIO -1% ) for KB001-A. Sanofi had been developing the monoclonal antibody ..... infections in cystic fibrosis patients. Sanofi agreed to terminate in consideration of

  6. The Product Development Story Of Provectus Biopharmaceuticals

    Headlines

    Mon, 28 Jul 2014

    the company has an advisory board composed of 2 senior executives of Pfizer (NYSE: PFE ), a senior executive of Sanofi (NYSE: SNY ), a senior executive Complete Story »

  7. Why Pfizer Will Trade At $40 On Improved Drug Pipeline

    Headlines

    Mon, 28 Jul 2014

    that is almost 30 points below Merck (NYSE: MRK ), 13 points below Novartis (NYSE: NVS ) and 15 point below Sanofi (NYSE: SNY ). This makes Pfizer a candidate for the best bargain in Big Pharma. What's more, with improved cash flow and

  8. XLV Health Care Select Sector SPDR® ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Thu, 24 Jul 2014

    companies, the index excludes international health-care behemoths such as Novartis NVS, GlaxoSmithKline GSK, Roche, and Sanofi SNY . That said, we'd note that most of the firms included here are large multinational firms with businesses spanning

  9. IYH iShares US Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Thu, 24 Jul 2014

    overseas. As a result, international health-care behemoths such as Novartis NVS, GlaxoSmithKline GSK, Roche, and Sanofi SNY are nowhere to be found. That said, many of the firms in this ETF have sales all over the globe, so investors still

  10. VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Thu, 24 Jul 2014

    domiciled in the United States, which means that it doesn't invest in foreign behemoths such as Novartis NVS, Roche, and Sanofi SNY . That said, many of the companies in VHT operate businesses spanning the globe, which ensures at least some exposure

« Prev12345Next »
Content Partners